Anzeige
Mehr »
Login
Montag, 29.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Fokus auf Nurexone: High-Level Biotech im Pennystock-Kleid!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
81 Leser
Artikel bewerten:
(0)

SHIRE PLC - Director/PDMR Shareholding

PR Newswire
London, April 4

Director/PDMR Shareholding

April 4, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company")

Notification of transactions by person discharging managerial responsibilities

1.Details of the person discharging managerial responsibilities ("PDMR") / person closely associated them ("PCA")
a)NameFlemming Ornskov
2.Reason for the notification
a)Position / statusChief Executive Officer - PDMR
b)Initial notification / amendmentInitial notification
3.Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
b)LEI54930005LQRLI2UXRQ59
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares ("ADSs")
Identification codeISIN: US82481R1068
b)Nature of the transactionRelease of ADSs awarded under the Shire Executive Annual Incentive on March 31, 2014. In accordance with the relevant plan rules, upon release the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the ADSs from the award date to the date of release.
(Details of related disposals of ADSs are referenced in sections 5. - 10. and the appendix below.)
c)Price(s) and volume(s)Price(s)Volume(s)
N/A2,735
d)Aggregated information
- Aggregated volume
- Price
N/A (single transaction)
e)Date of the transactionMarch 31, 2017
f)Place of the transactionN/A
5.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares ("ADSs")
Identification codeISIN: US82481R1068
b)Nature of the transactionAutomated disposal of ADSs in relation to the release of ADSs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the release of the ADSs.
(See appendix below for aggregate disposal details.)
c)Price(s) and volume(s)Price(s)Volume(s)
$174.932
$175.105
$175.2810
$175.28100
$175.27100
$175.13100
$175.23100
$175.18100
d)Aggregated information
- Aggregated volume
- Price
Weighted average priceAggregate volume
$175.22517
e)Date of the transactionMarch 31, 2017
f)Place of the transactionARCX
6.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares ("ADSs")
Identification codeISIN: US82481R1068
b)Nature of the transactionAutomated disposal of ADSs in relation to the release of ADSs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the release of the ADSs.
(See appendix below for aggregate disposal details.)
c)Price(s) and volume(s)Price(s)Volume(s)
$175.35100
$175.30100
$175.34100
$175.28100
$175.28100
$175.30100
d)Aggregated information
- Aggregated volume
- Price
Weighted average priceAggregate volume
$175.31600
e)Date of the transactionMarch 31, 2017
f)Place of the transactionDBAX
7.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares ("ADSs")
Identification codeISIN: US82481R1068
b)Nature of the transactionAutomated disposal of ADSs in relation to the release of ADSs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the release of the ADSs.
(See appendix below for aggregate disposal details.)
c)Price(s) and volume(s)Price(s)Volume(s)
$175.31100
$175.31100
$175.29100
d)Aggregated information
- Aggregated volume
- Price
Weighted average priceAggregate volume
$175.30300
e)Date of the transactionMarch 31, 2017
f)Place of the transactionIEXG
8.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares ("ADSs")
Identification codeISIN: US82481R1068
b)Nature of the transactionAutomated disposal of ADSs in relation to the release of ADSs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the release of the ADSs.
(See appendix below for aggregate disposal details.)
c)Price(s) and volume(s)Price(s)Volume(s)
$175.11100
d)Aggregated information
- Aggregated volume
- Price
N/A (single transaction)
e)Date of the transactionMarch 31, 2017
f)Place of the transactionBOSX
9.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares ("ADSs")
Identification codeISIN: US82481R1068
b)Nature of the transactionAutomated disposal of ADSs in relation to the release of ADSs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the release of the ADSs.
(See appendix below for aggregate disposal details.)
c)Price(s) and volume(s)Price(s)Volume(s)
$175.27100
d)Aggregated information
- Aggregated volume
- Price
N/A (single transaction)
e)Date of the transactionMarch 31, 2017
f)Place of the transactionCSDK
10.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares ("ADSs")
Identification codeISIN: US82481R1068
b)Nature of the transactionAutomated disposal of ADSs in relation to the release of ADSs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the release of the ADSs.
(See appendix below for aggregate disposal details.)
c)Price(s) and volume(s)Price(s)Volume(s)
$175.18100
d)Aggregated information
- Aggregated volume
- Price
N/A (single transaction)
e)Date of the transactionMarch 31, 2017
f)Place of the transactionEDGX

Appendix

Place of the transactionAggregate volumeWeighted average price
ARCX517$175.22
BOSX100$175.11
CSDK100$175.27
DBAX600$175.31
EDGX100$175.18
IEXG300$175.30
Total1,717$175.26

Oliver Strawbridge

Senior Assistant Company Secretary

For further information please contact:

Investor Relations
Ian Karpikarp@shire.com+1 781 482 9018
Robert Coatesrcoates@shire.com+44 1256 894874
Media
Lisa Adlerlisa.adler@shire.com+1 617 588 8607
Debbi Forddebbi.ford@shire.com+1 617 949 9083

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

www.shire.com

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.